Jeffrey Ward, MD, PhD

Medical Oncologist

Jeffrey Ward

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Video thumbnail for Jeffrey Ward, MD, PhD

Watch video on YouTube

Jeffrey Ward, MD, PhD

2 mins

Washington University medical oncologist Jeffrey Ward, MD, PhD, discusses what lung cancer patients can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Ward: https://siteman.wustl.edu/doctor/ward-jeffrey/

Learn more about the Siteman Approach to Lung Cancer: https://siteman.wustl.edu/treatment/cancer-types/lung-cancer/our-approach/

Lung cancer screening is improving patient outcomes at Siteman. Learn more: https://siteman.wustl.edu/how-siteman-is-revolutionizing-lung-cancer-screening-and-improving-patient-outcomes/

Meet the Siteman Cancer Center Lung Cancer Specialist Team: https://siteman.wustl.edu/treatment/cancer-types/lung-cancer/specialist-team/

Clinical Expertise

  • Lung Cancer

Primary Academic Title

Associate Professor of Medicine, Division of Medical Oncology, WashU Medicine

Training

  • 2010 - 2011 : Intern, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO
  • 2011 - 2012: Resident, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO
  • 2012 - 2016: Fellow, Hematology/Oncology, WashU Medicine, St. Louis, MO

Education

  • 2010: MD, PhD, State University of New York Upstate Medical University, Syracuse, NY

Research & Selected Publications

Research Interest

The clinical development and introduction into practice of checkpoint inhibitors that reinvigorate the immune system to target tumors have revolutionized the treatment paradigm for patients with lung cancer.

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Authors:

Sultan H, Takeuchi Y, Ward JP, one or more additional authors omitted Schreiber RD

Journal & Year:

Nature | 2024

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after plati…
Authors:

Leal T, Kotecha R, Ramlau R, one or more additional authors omitted Ward J, one or more additional authors omitted Langer C

Journal & Year:

Lancet Oncol | 2023